Breast Cancer
Conditions
Keywords
lung inflammation, lung metastases, 10-115
Brief summary
The purpose of this study is to find out if there is a link between cigarette smoking, inflammation and the spread of breast cancer to the lung. We think that women who are current or former smokers may be at increased risk for breast cancer spreading to the lung compared to women who have never smoked. Smoking causes inflammation in the lung in some women. Researchers at Memorial Sloan-Kettering (MSKCC) think that smoking-related lung inflammation may increase the chance of breast cancer spreading to the lung. In order to find out whether inflammation plays a role in breast cancer spreading to the lung, we will measure a urinary marker of lung inflammation. This will allow us to determine if this marker is more commonly elevated in women with breast cancer that has spread to the lung compared to those without breast cancer in the lung. We will also collect DNA from blood to have the opportunity to determine if there are differences in DNA in women with or without breast cancer that has spread to the other sites including the lung. We will also collect blood to determine if we can identify risk factors for the spread of breast cancer to the lungs.
Interventions
BEHAVIORALquestionnaire, blood draw and urine sample
Patients will be asked to participate on a single day. After study registration they will be asked to complete the questionnaire. All participants will complete a questionnaire detailing tobacco and NSAID exposure, as well as detailing any other inflammatory conditions of the lung. Then the patient will give a single blood sample (up to 3 tubes) and a single urine sample.
Sponsors
Weill Medical College of Cornell University
Vanderbilt University
Memorial Sloan Kettering Cancer Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Registered patient at MSKCC * Histologically proven breast cancer. It is not necessary that pathology be reviewed at MSKCC * Age ≥18 years Group 1 (A and B) * Diagnosed with metastatic breast cancer on biopsy or imaging study. * Patients will be considered to have lung metastases, and will be assigned to group 1A if any of the following criteria are met, otherwise patients will be assigned to group 1B No known Lung Metastases, Biopsy-proven lung metastasis. * Pleural effusion with cytologic evidence of malignancy. * Pleural effusion, exudative in character, without alternative explanation and attributed, in the opinion of the clinician to metastatic disease. * Symptoms attributable to lung metastases and a radiological pattern interpreted by a radiologist as suspicious for metastatic disease. * Any pulmonary nodule on chest radiograph, CT scan, PET-CT or MRI, which is interpreted by the clinician and radiologist to be metastatic in etiology, whether or not a biopsy was performed, and regardless of symptoms. * A radiographic pattern interpreted by a radiologist as consistent with lymphangitic carcinomatosis. Group 2 (Controls) * History of early breast cancer and currently no evidence of disease
Exclusion criteria
* Inability to provide written informed consent. * Inability to complete smoking and NSAID questionnaire. * Steroid use within the previous 4 weeks. * Radiotherapy to the breast, chest wall or axilla within the previous 3 months. * Men with breast cancer.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The association between urinary PGE-M and the presence or absence of lung metastases | 2 years | in patients with breast cancer |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The putative link between smoking and site-specific metastases from breast cancer | 2 years | — |
| Polymorphisms for genes linked to inflammation (germ line DNA SNPs) | 2 years | with the presence or absence of lung metastases. |
Countries
United States
Outcome results
None listed